The ACT-Accelerator's commitment to equity remains urgent in light of persistent gaps in access to COVID-19 tools.
77 x more tests are being carried out per 1,000 people daily in high-income countries than in low-income ones
Only just over 15% of people in low-income countries have received at least one dose
Funding vital research and development of new therapeutics, vaccines, and diagnostics.
Procuring 175.7 million tests and more than $767 million worth of PPE
Supporting the market entry of new, affordable rapid tests.
Delivering more than 1.7 billion COVID-19 vaccine doses via the vaccines pillar, COVAX
Procuring over US$578 million worth of medical oxygen supplies and repairing 180 PSA plants
As of: 21 Sept 2022
Read about the ACT-Accelerator's impact in our quarterly and annual reports: